The advent of artificial intelligence (AI) has clearly changed the world, but not all uses of AI have necessarily made the world a better place. In fact, a recent PwC study found that 56% of CEOs are yet to see significant benefits from their AI investments.
But if there’s one area where artificial intelligence has the potential to bring about meaningful change for the better, it’s probably in healthcare, where everything seems complicated. Here’s a closer look at two healthcare stocks that are uniquely harnessing the power of AI to grow their businesses and reward shareholders as a result.
Image source: Getty Images.
recursion medicine
Do you know how much it costs to bring a single drug to market? The U.S. Department of Health and Human Services puts the average at nearly $900 million, but similarly reliable estimates suggest the number could reach $2 billion, if not more. To make matters worse, the National Institutes of Health estimates that 9 out of 10 drugs that begin clinical trials ultimately fail to win approval. don’t worry year All of these preclinical and clinical trials need to be done.
But what if there was a way to do much of this research and development (R&D) work virtually in hours and at a fraction of the usual cost? recursion medicine (RXRX +8.10%) provided to customers.
recursion medicine
Today’s changes
(8.10%) $0.23
current price
$3.07
Key data points
Market capitalization
$1.6 billion
daily range
$2.90 – $3.07
52 week range
$2.80 – $7.18
volume
241K
average volume
19M
gross profit
-6195.95%
To be clear, this is not a replacement for a clinical trial. But Recursion’s AI-powered platform, based on more than 50 petabytes (52.4 million gigabytes) of chemical and biological data, gives drug developers a much better idea of how their drugs will work in the real world. This allows pharmaceutical companies to focus on the most promising prospects and avoids wasting resources on unprofitable work.
And this is not just a theory. In addition to using its technology to pre-test its drugs, Recursion also partners with more traditional pharmaceutical companies, including: sanofi and roche holding To unlock the potential of these third-party players.
The business is still in its early stages. Most of its operating revenue to date comes from paying drug company partners to virtually test their research and development ideas. But last year was a pivotal year for the company, with development milestone payments starting to begin in earnest. After modest sales growth this year, even greater revenue growth is expected in the next financial year. Recursion Pharmaceuticals is aggressively entering the AI-powered drug development market, which Global Market Insights predicts will grow at an average annual growth rate of 30% through 2035.
Tempus AI
Another AI healthcare stock to consider buying sooner rather than later is more of a technology name than healthcare, but it’s still a great opportunity. it is Tempus AI (TEM +6.73%).
Simply put, Tempus empowers caregivers. Although its user interface looks and acts like a regular web portal, it actually helps healthcare providers “make data-driven decisions in near real-time to deliver personalized patient care,” including “discovering, developing, and delivering optimal treatments.” No, there is nothing else like it.
Today’s changes
(6.73%) $2.85
current price
$45.22
Key data points
Market capitalization
$8.1 billion
daily range
$43.00 – $45.54
52 week range
$36.22 – $104.32
volume
114K
average volume
5.5M
gross profit
61.46%
But that’s not the premise that makes this stock’s prospects so attractive. That means it’s already up and running and off to the races. Tempus’ paying customers clearly like what they’re getting. The company’s fourth-quarter revenue was $367 million, up 83% year-over-year and moving it closer to breakeven, which it expects to do as early as next year.
After reading this, you might want to try Tempus. The current analyst consensus target of $77.93 is 70% above the stock’s current price.
#Healthcare #Stocks #Buy #Motley #Fool